Almac
Almac provides a range of integrated services from research through pharmaceutical and clinical development to commercialisation of product. Almac is a financially stable, privately owned organisation with over 3,300 employees located in the UK and US. Over 95% of work is repeat business, testament itself to the quality, efficiency and high level of customer satisfaction achieved.
Almac has completed its GMP manufacturing facility expansion and highly potent APIs (Phase 1 to commercial) can now be manufactured in batches up to 150 kg.
The company is now in able to offer all the services required to manufacture 14C-labelled antibody drug conjugates, making a real impact on first in human study programmes.
In addition, Almac recently invested $10 million to a new non-GMP pharmaceutical development facility, enhancing speed and flexibility by providing streamlined progression between development and GMP phases of projects. A further $10 million investment was made in a 9,290 m2 facility in Audubon, Pennsylvania, US, which offers quality, flexible US commercial packaging solutions for solid oral and sterile biopharmaceutical drug products.
Almac’s clinical service offering has been further expanded by the introduction of contained drug handling capabilities both in Europe and the US, thus enabling the company to now dispense and bottle solid dosage products.
Stand 42L08
Almac Group Ltd, +44 28 3833 2200, info@almacgroup.com, www.almacgroup.com.